

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Krishnan Suma</u>  (Last) (First) (Middle) C/O KRYSAL BIOTECH, INC. 2100 WHARTON STREET, SUITE 701  (Street) PITTSBURGH PA 15203  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Krystal Biotech, Inc. [ KRY5 ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President, R&D
	3. Date of Earliest Transaction (Month/Day/Year) 04/17/2023	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/17/2023		S <sup>(1)</sup>		1,050	D	\$85.5487 <sup>(2)</sup>	1,673,156	D	
Common Stock	04/17/2023		S <sup>(1)</sup>		4,297	D	\$86.7964 <sup>(3)</sup>	1,668,859	D	
Common Stock	04/17/2023		S <sup>(1)</sup>		9,429	D	\$87.4114 <sup>(4)</sup>	1,659,430	D	
Common Stock	04/17/2023		S <sup>(1)</sup>		9,724	D	\$88.4062 <sup>(5)</sup>	1,649,706	D	
Common Stock	04/17/2023		S <sup>(1)</sup>		500	D	\$89.1175 <sup>(6)</sup>	1,649,206	D	
Common Stock	04/17/2023		S <sup>(7)</sup>		1,050 <sup>(8)</sup>	D	\$85.5483 <sup>(2)</sup>	1,737,638	I	By Spouse <sup>(9)</sup>
Common Stock	04/17/2023		S <sup>(7)</sup>		4,298 <sup>(8)</sup>	D	\$86.7964 <sup>(3)</sup>	1,733,340	I	By Spouse <sup>(9)</sup>
Common Stock	04/17/2023		S <sup>(7)</sup>		9,428 <sup>(8)</sup>	D	\$87.4113 <sup>(4)</sup>	1,723,912	I	By Spouse <sup>(9)</sup>
Common Stock	04/17/2023		S <sup>(7)</sup>		9,724 <sup>(8)</sup>	D	\$88.4062 <sup>(5)</sup>	1,714,188	I	By Spouse <sup>(9)</sup>
Common Stock	04/17/2023		S <sup>(7)</sup>		500 <sup>(8)</sup>	D	\$89.1175 <sup>(6)</sup>	1,713,688	I	By Spouse <sup>(9)</sup>
Common Stock								90,000	I	By SMK Trust
Common Stock								50,000	I	By Krishnan Family Trust <sup>(10)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

**Explanation of Responses:**

- The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of \$80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan.
- The transaction was executed in multiple trades ranging from \$85.0500 to \$86.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The transaction was executed in multiple trades ranging from \$86.0500 to \$87.0450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The transaction was executed in multiple trades ranging from \$87.0500 to \$88.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to

- provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
5. The transaction was executed in multiple trades ranging from \$88.0500 to \$89.0100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  6. The transaction was executed in multiple trades ranging from \$89.0650 to \$89.2300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  7. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of \$80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan.
  8. These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.
  9. Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.
  10. Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.

**Remarks:**

/s/ Suma Krishnan

04/18/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**